MEDI4736, MEDI4736 w/Tremelimumab, or Ordinary Care in SCCHN

This is a randomized, open-label, multi-center, global, Phase III study to the efficacy and safety of MEDI4736 as monotherapy and MEDI4736 + tremelimumab combination therapy versus SoC therapy in the target patient population.

January 19, 2016